Neuroprotective effect of tyrosol on transient focal cerebral ischemia in rats.
Tyrosol (2-(4-hydroxyphenyl)ethanol) is a well-known phenolic compound with antioxidant properties that is present in wine, olive oil, and other plant-derived products. The purpose of this study was to determine the neuroprotective effect of tyrosol in a stroke animal model. By using the transient middle cerebral artery occlusion rat model (2 h of occlusion, 22 h of reperfusion), we investigated the effects of tyrosol on infarct volume and sensory motor function deficit by performing 2,3,5-triphenyltetrazolium chloride staining and behavior tests after ischemia. Tyrosol showed a dose-dependent neuroprotective effect that peaked at 64.9% in rats treated with 30 mg/kg of tyrosol. In rotarod, beam balance, and foot fault tests, tyrosol exhibited protective effects against the sensory motor dysfunction. In conclusion, our results suggest that tyrosol is an appropriate candidate to be used in stroke therapy.
Bu
Youngmin
Y
Department of Herbal Pharmacology, College of Pharmacy, Woosuk University, Chonbuk 565-701, South Korea.
Rho
Seongjoo
S
Kim
Jinmo
J
Kim
Mi Yeon
MY
Lee
Dae Hee
DH
Kim
Sun Yeou
SY
Choi
Hoyoung
H
Kim
Hocheol
H
D000818:Animals; D000975:Antioxidants / Q000494:pharmacology* / Q000627:therapeutic use; D001921:Brain / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D002544:Cerebral Infarction / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control; D004305:Dose-Response Relationship, Drug; D020244:Infarction, Middle Cerebral Artery / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D002546:Ischemic Attack, Transient / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D008297:Male; D009069:Movement Disorders / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D018696:Neuroprotective Agents / Q000494:pharmacology* / Q000627:therapeutic use; D010626:Phenylethyl Alcohol / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley; D012678:Sensation Disorders / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D013778:Tetrazolium Salts; D016896:Treatment Outcome
D000975:Antioxidants; D018696:Neuroprotective Agents; D013778:Tetrazolium Salts; C011867:4-hydroxyphenylethanol; D010626:Phenylethyl Alcohol